Is Disc Medicine Stock a Good Investment?
Disc Medicine Investment Advice | IRON |
- Examine Disc Medicine's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Disc Medicine's leadership team and their track record. Good management can help Disc Medicine navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Disc Medicine's business and its evolving consumer preferences.
- Compare Disc Medicine's performance and market position to its competitors. Analyze how Disc Medicine is positioned in terms of product offerings, innovation, and market share.
- Check if Disc Medicine pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Disc Medicine's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Disc Medicine stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Disc Medicine is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Disc Medicine Stock
Researching Disc Medicine's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 79.0% of the company shares are owned by institutional investors. The book value of Disc Medicine was currently reported as 14.85. The company recorded a loss per share of 3.96. Disc Medicine had not issued any dividends in recent years. The entity had 1:30 split on the 30th of December 2022.
To determine if Disc Medicine is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Disc Medicine's research are outlined below:
| Disc Medicine generated a negative expected return over the last 90 days | |
| Net Loss for the year was (109.36 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Disc Medicine generates negative cash flow from operations | |
| Over 79.0% of the company shares are owned by institutional investors | |
| Latest headline from kalkinemedia.com: Is Disc Medicine Gaining Institutional Confidence |
Disc Medicine uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Disc Medicine. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Disc Medicine's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Disc Medicine's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Disc Medicine's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-11-10 | 2022-09-30 | -0.09 | -0.08 | 0.01 | 11 | ||
2024-03-21 | 2023-12-31 | -0.78 | -0.9 | -0.12 | 15 | ||
2023-08-11 | 2023-06-30 | -0.86 | -0.74 | 0.12 | 13 | ||
2025-03-19 | 2024-12-31 | -1.1036 | -0.98 | 0.1236 | 11 | ||
2024-11-07 | 2024-09-30 | -1.05 | -0.8885 | 0.1615 | 15 | ||
2023-11-09 | 2023-09-30 | -0.8 | -0.58 | 0.22 | 27 | ||
2022-08-11 | 2022-06-30 | -2 | -1.6 | 0.4 | 20 | ||
2023-03-31 | 2022-12-31 | -0.76 | -1.22 | -0.46 | 60 |
Disc Medicine's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.84 B.Market Cap |
|
Disc Medicine's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.24) | (0.25) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.25) | (0.24) |
Determining Disc Medicine's profitability involves analyzing its financial statements and using various financial metrics to determine if Disc Medicine is a good buy. For example, gross profit margin measures Disc Medicine's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Disc Medicine's profitability and make more informed investment decisions.
Evaluate Disc Medicine's management efficiency
Disc Medicine has return on total asset (ROA) of (0.1875) % which means that it has lost $0.1875 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2773) %, meaning that it created substantial loss on money invested by shareholders. Disc Medicine's management efficiency ratios could be used to measure how well Disc Medicine manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of March 2025, Return On Tangible Assets is likely to drop to -0.2. In addition to that, Return On Capital Employed is likely to drop to -0.25. As of the 22nd of March 2025, Other Assets is likely to grow to about 217.3 K, while Total Assets are likely to drop about 281.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 17.79 | 25.67 | |
| Tangible Book Value Per Share | 17.79 | 25.67 | |
| Enterprise Value Over EBITDA | (11.76) | (11.17) | |
| Price Book Value Ratio | 3.36 | 3.53 | |
| Enterprise Value Multiple | (11.76) | (11.17) | |
| Price Fair Value | 3.36 | 3.53 | |
| Enterprise Value | 837.6 M | 879.5 M |
The management team at Disc Medicine has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Beta 2.845 |
Basic technical analysis of Disc Stock
As of the 22nd of March, Disc Medicine shows the Standard Deviation of 2.12, mean deviation of 1.72, and Variance of 4.49. Disc Medicine technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Disc Medicine's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Disc Medicine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Disc Medicine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Disc Medicine insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Disc Medicine's Outstanding Corporate Bonds
Disc Medicine issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Disc Medicine uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Disc bonds can be classified according to their maturity, which is the date when Disc Medicine has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US254687DD54 Corp BondUS254687DD54 | View | |
| DIS 77 30 OCT 25 Corp BondUS254687DF03 | View | |
| DISNEY WALT NEW Corp BondUS25468PCP99 | View | |
| DISNEY WALT NEW Corp BondUS25468PCR55 | View | |
| US254687DH68 Corp BondUS254687DH68 | View | |
| DISNEY WALT NEW Corp BondUS25468PBW59 | View | |
| WALT DISNEY CO Corp BondUS254687FL52 | View | |
| WALT DISNEY CO Corp BondUS254687FM36 | View |
Understand Disc Medicine's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Disc Medicine's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | (0.33) | |||
| Mean Deviation | 1.72 | |||
| Coefficient Of Variation | (805.21) | |||
| Standard Deviation | 2.12 | |||
| Variance | 4.49 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.21) | |||
| Total Risk Alpha | (0.10) | |||
| Treynor Ratio | (0.34) | |||
| Maximum Drawdown | 8.7 | |||
| Value At Risk | (3.34) | |||
| Potential Upside | 3.08 | |||
| Skewness | 0.0406 | |||
| Kurtosis | (0.47) |
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | (0.33) | |||
| Mean Deviation | 1.72 | |||
| Coefficient Of Variation | (805.21) | |||
| Standard Deviation | 2.12 | |||
| Variance | 4.49 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.21) | |||
| Total Risk Alpha | (0.10) | |||
| Treynor Ratio | (0.34) | |||
| Maximum Drawdown | 8.7 | |||
| Value At Risk | (3.34) | |||
| Potential Upside | 3.08 | |||
| Skewness | 0.0406 | |||
| Kurtosis | (0.47) |
Consider Disc Medicine's intraday indicators
Disc Medicine intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Disc Medicine stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 39090.55 | |||
| Daily Balance Of Power | (0.51) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 53.04 | |||
| Day Typical Price | 52.77 | |||
| Price Action Indicator | (1.29) | |||
| Period Momentum Indicator | (0.99) | |||
| Relative Strength Index | 37.18 |
Disc Medicine Corporate Filings
| 18th of March 2025 Other Reports | ViewVerify | |
F3 | 25th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
10K | 21st of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
| 31st of January 2025 Other Reports | ViewVerify |
Disc Stock media impact
Far too much social signal, news, headlines, and media speculation about Disc Medicine that are available to investors today. That information is available publicly through Disc media outlets and privately through word of mouth or via Disc internal channels. However, regardless of the origin, that massive amount of Disc data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Disc Medicine news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Disc Medicine relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Disc Medicine's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Disc Medicine alpha.
Disc Medicine Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Disc Medicine can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Disc Medicine Maximum Pain Price Across June 20th 2025 Option Contracts
Disc Medicine's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Disc Medicine close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Disc Medicine's options.
Disc Medicine Corporate Management
| Jonathan Yu | Chief Officer | Profile | |
| Rahul Kaushik | Chief Officer | Profile | |
| Joanne CPA | Chief Officer | Profile | |
| William MD | Chief Officer | Profile | |
| Pamela MPH | Chief Officer | Profile | |
| Jean CPA | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Disc Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Disc Stock, please use our How to Invest in Disc Medicine guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Disc Medicine. If investors know Disc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Disc Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Disc Medicine is measured differently than its book value, which is the value of Disc that is recorded on the company's balance sheet. Investors also form their own opinion of Disc Medicine's value that differs from its market value or its book value, called intrinsic value, which is Disc Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Disc Medicine's market value can be influenced by many factors that don't directly affect Disc Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Disc Medicine's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Disc Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Disc Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.